SCHEMBL5017370

SCHEMBL5017370

Cc1ccc(-c2[nH]c(=O)c3ccccc3c2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 3/20 0.55
PARP1 P09874 6/20 0.49
TNKS O95271 5/20 0.49
TNKS2 Q9H2K2 5/20 0.49
MAOA P21397 2/20 0.49
MAOB P27338 1/20 0.49
CDC25B P30305 1/20 0.43
UBE2I P63279 1/20 0.43
SAE1 Q9UBE0 1/20 0.43
UBA2 Q9UBT2 1/20 0.43
RAB9A P51151 2/20 0.43
CTSV O60911 1/20 0.43
CTSL P07711 1/20 0.43
HPGD P15428 1/20 0.43
NPC1 O15118 1/20 0.42
PTGS2 P35354 2/20 0.41
PDE9A O76083 1/20 0.41
PDE1C Q14123 1/20 0.41
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31047679 0.86 SERPINE1 (0.65) SERPINE1PARP1TNKSTNKS2MAOA
SCHEMBL14867264 0.85 MAOA (0.48) SERPINE1PARP1TNKSTNKS2MAOA
SCHEMBL29639169 0.81 PTGS2 (0.56) SERPINE1PARP1TNKSTNKS2RAB9A
SCHEMBL29031852 0.81 PTGS2 (0.56) SERPINE1PARP1TNKSTNKS2RAB9A
SCHEMBL14867250 0.80 PARP1 (0.54) SERPINE1PARP1TNKSTNKS2CDC25B
SCHEMBL31047695 0.80 PARP1 (0.49) SERPINE1PARP1TNKSTNKS2CDC25B
SCHEMBL29031885 0.79 SERPINE1 (0.56) SERPINE1PARP1TNKSTNKS2RAB9A
SCHEMBL30472330 0.79 SERPINE1 (0.56) SERPINE1PARP1TNKSTNKS2RAB9A
SCHEMBL14867286 0.78 KDM4E (0.50) SERPINE1TNKSTNKS2MAOAMAOB
SCHEMBL14867248 0.75 HPRT1 (0.46) SERPINE1PARP1TNKSTNKS2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1729720-B1 COMPOSITION COMPRISING A POLYMER COMPRISING A MONOMER COMPOUND EXHIBITING AN OPTICAL PROPERTY, METHOD MAKING USE OF SAID COMPOSITION OREAL (FR) 2008-11-19 EP disclosed
US-20070191562-A1 Composition comprising a monomer compound exhibiting an optical property, method making use of said composition, a monomer compound, a polymer containing said monomer compound and the use thereof L'OREAL S.A. (FR) 2007-08-16 US disclosed
EP-1729720-A1 COMPOSITION COMPRISING A MONOMER COMPOUND EXHIBITING AN OPTICAL PROPERTY, METHOD MAKING USE OF SAID COMPOSITION, A MONOMER COMPOUND, A POLYMER CONTAINING SAID MONOMER COMPOUND AND THE USE THEREOF L'OREAL (FR) 2006-12-13 EP disclosed
WO-2006005823-A1 DISPERSION OF ETHYLENE POLYMER PARTICLES, COMPOSITION CONTAINING SAME AND TREATMENT METHOD L'OREAL (FR) 2006-01-19 WO disclosed
US-20050271616-A1 Novel block polymers, compositions comprising them, and processes for treating kerating materials therewith L'OREAL S.A. (FR) 2005-12-08 US disclosed
WO-2005102249-A1 COMPOSITION COMPRISING A MONOMER COMPOUND EXHIBITING AN OPTICAL PROPERTY, METHOD MAKING USE OF SAID COMPOSITION, A MONOMER COMPOUND, A POLYMER CONTAINING SAID MONOMER COMPOUND AND THE USE THEREOF L'OREAL (FR) 2005-11-03 WO disclosed
EP-1580203-A1 New blockpolymers, compositions comprising the same and use thereof L'OREAL (FR) 2005-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050271616-A1 Novel block polymers, compositions comprising them, and processes for treating kerating materials therewith KRT18, TUBB, TUBB4B SERPINE1 282/4885PARP1 1718/4885TNKS 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.